CORI is “a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products…”
The $8 IPO price was down from the previously anticipated range of $10-12. The flat first day of trading is a good sign for biotech investors, IMO.
*Assuming exercise of underwriter’s option.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”